Managing Symptoms and Treatment Options for MEPAN
At a Glance
MEPAN has no proven treatment that stops or reverses the disease. Care focuses on easing dystonia and stiffness, supporting swallowing, communication, vision, and daily function; medicines are individualized, while DBS and lipoic acid remain experimental or uncertain.
At this time, there is no disease-modifying cure that can stop or reverse the progression of MEPAN syndrome. Because of this, medical care is focused entirely on symptom management: reducing the physical impact of movement challenges, supporting vision, and maintaining the highest possible quality of life [1][2].
Managing Dystonia with Medication
For many patients with MEPAN, the first step in treatment is using medications to relax muscles and reduce the intensity of dystonia (involuntary muscle contractions). Medication choice and sequencing are highly individualized based on movement patterns, age, and function.
- Oral Baclofen: This medication acts in the central nervous system and is often used if a patient also has spasticity (muscle stiffness). It works by signaling the muscles to relax [3]. Medication Safety: Baclofen can cause clinically important side effects like sedation and weakness. It must be tapered under careful prescriber supervision rather than stopped abruptly, as sudden withdrawal can cause severe, dangerous symptoms [4][5].
- Trihexyphenidyl: This medication is frequently used for dystonia. While it can be helpful, its use is sometimes limited by side effects like constipation, dry mouth, urinary retention, or heat intolerance [6][7]. Always contact the prescriber before changing doses.
- Botulinum Toxin (Botox): If the dystonia is most severe in one specific area—such as the legs or arms—injections of botulinum toxin can help relax those specific muscles. This is most useful for improving comfort, positioning in a wheelchair, or making daily care easier [8][3].
Surgical Options: Deep Brain Stimulation (DBS)
For patients whose dystonia is severe and does not respond well to medications, a surgical procedure called Deep Brain Stimulation (DBS) may be considered. DBS involves placing thin electrodes into specific “control centers” of the brain, most commonly the globus pallidus (GPi), and connecting them to a device similar to a pacemaker [1][9].
It is important to understand that DBS is an investigational or highly specialized option based on very limited case-series evidence:
- In one small report of two children with MEPAN, DBS significantly improved scores on dystonia rating scales with no reported perioperative complications [1].
- However, expected benefit and durability remain uncertain, and DBS does not treat optic atrophy or the underlying disease.
- Risks: DBS carries serious risks including bleeding, infection, seizures, hardware problems, anesthesia risks, and the need for frequent programming and battery procedures.
The Role of Metabolic Supplements
Because MEPAN is caused by a disruption in mitochondrial metabolism, some families and doctors have considered using lipoic acid as a supplement. However, it is important to understand that this is currently experimental and not a proven treatment [10].
- Evidence in the Lab: In a laboratory model using yeast, adding lipoic acid helped the cells grow more normally [10].
- Evidence in Animals: In a mouse model of MEPAN, a combination of lipoic acid and certain fats (medium-chain triglycerides) did not stop the death of brain cells [11].
- Evidence in Humans: There are currently no large clinical trials showing that lipoic acid changes the course of the disease in humans. A single case report described lipoic acid alongside controlled disease progression, but this is an individual observation, not established efficacy. You should discuss the potential risks with a metabolic specialist [11].
Supportive Care and Quality of Life
Beyond medications and surgery, non-drug therapies are the “backbone” of care for MEPAN:
- Physical and Occupational Therapy: These therapies focus on maintaining joint flexibility to prevent contractures (permanent shortening of muscles) and finding adaptive equipment to help with mobility and pain [1][2].
- Speech Therapy and AAC: As dystonia affects the muscles used for speaking (dysarthria), a speech therapist can help. For patients whose speech is difficult to understand or who have limited functional speech, Augmentative and Alternative Communication (AAC) devices can supplement speech and ensure they can express their thoughts [12][13].
- Nutritional Support and Swallowing: Dystonia can affect swallowing (dysphagia). If choking, coughing, or poor weight gain occurs, a speech-language pathologist or feeding team should guide care. Do not independently choose texture-modified foods, as aspiration may be silent; FEES or videofluoroscopy is used when a clinical assessment indicates it [14][15].
- Low-Vision Support: To manage optic atrophy, referrals to low-vision optometry and rehabilitation are crucial. While these do not restore damaged nerve fibers, they improve function through magnification, screen-reader technology, orientation and mobility training, and workplace/school accommodations.
Common questions in this guide
Is there a cure that stops MEPAN syndrome from getting worse?
Which medicines are used for MEPAN-related dystonia?
When might deep brain stimulation be considered for MEPAN?
Are lipoic acid or medium-chain triglycerides proven treatments for MEPAN?
What supportive therapies can help a person with MEPAN?
Get notified when new evidence is published on MEPAN syndrome.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (15)
- 1
Application of deep brain stimulation for the treatment of childhood-onset dystonia in patients with MEPAN syndrome.
Nataraj J, MacLean JA, Davies J, et al.
Frontiers in neurology 2023; (14()):1307595 doi:10.3389/fneur.2023.1307595.
PMID: 38328756 - 2
MECR Mutations Cause Childhood-Onset Dystonia and Optic Atrophy, a Mitochondrial Fatty Acid Synthesis Disorder.
Heimer G, Kerätär JM, Riley LG, et al.
American journal of human genetics 2016; (99(6)):1229-1244 doi:10.1016/j.ajhg.2016.09.021.
PMID: 27817865 - 3
Pharmacological and neurosurgical interventions for individuals with cerebral palsy and dystonia: a systematic review update and meta-analysis.
Bohn E, Goren K, Switzer L, et al.
Developmental medicine and child neurology 2021; (63(9)):1038-1050 doi:10.1111/dmcn.14874.
PMID: 33772789 - 4
Baclofen Toxicity in Children With Acute Kidney Injury: Case Reports and Review of the Literature.
Mishaal RA, Lanphear NE, Armarnik E, et al.
Child neurology open 2020; (7()):2329048X20937113 doi:10.1177/2329048X20937113.
PMID: 32637443 - 5
Efficacy and safety of oral baclofen in the management of spasticity: A rationale for intrathecal baclofen.
Ertzgaard P, Campo C, Calabrese A
Journal of rehabilitation medicine 2017; (49(3)):193-203 doi:10.2340/16501977-2211.
PMID: 28233010 - 6
Medication use in childhood dystonia.
Lumsden DE, Kaminska M, Tomlin S, Lin JP
European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society 2016; (20(4)):625-9.
PMID: 26924167 - 7
Clinical Presentations and Treatment of Baclofen Toxicity and Withdrawal: A Systematic Review.
Iqbal M, Modi P, Sehgal K, et al.
CNS drugs 2026; (40(3)):419-449 doi:10.1007/s40263-025-01254-9.
PMID: 41555041 - 8
Update on current and emerging therapies for dystonia.
Lizarraga KJ, Al-Shorafat D, Fox S
Neurodegenerative disease management 2019; (9(3)):135-147 doi:10.2217/nmt-2018-0047.
PMID: 31117876 - 9
Novel utilization of deep brain stimulation in the pedunculopontine nucleus with globus pallidus internus for treatment of childhood-onset dystonia.
MacLean JA, Nataraj J, Davies J, et al.
Frontiers in human neuroscience 2023; (17()):1270430 doi:10.3389/fnhum.2023.1270430.
PMID: 37929227 - 10
Recessive MECR pathogenic variants cause an LHON-like optic neuropathy.
Fiorini C, Degiorgi A, Cascavilla ML, et al.
Journal of medical genetics 2023; (61(1)):93-101 doi:10.1136/jmg-2023-109340.
PMID: 37734847 - 11
Exploration of dietary interventions to treat mitochondrial fatty acid disorders in a mouse model.
Autio KJ, Koivisto H, Schmitz W, et al.
The Journal of nutritional biochemistry 2024; (131()):109692 doi:10.1016/j.jnutbio.2024.109692.
PMID: 38879137 - 12
Speech characteristics in the congenital and childhood-onset forms of myotonic dystrophy type 1.
Sjögreen L, Mårtensson Å, Ekström AB
International journal of language & communication disorders 2018; (53(3)):576-583 doi:10.1111/1460-6984.12370.
PMID: 29327796 - 13
Early-onset generalized dystonia caused by a new mutation in the KMT2B gene: Case report
Rangel YA, Espinosa E
Biomedica : revista del Instituto Nacional de Salud 2022; (42(3)):429-434 doi:10.7705/biomedica.6296.
PMID: 36122281 - 14
Failure to thrive - an overlooked manifestation of KMT2B-related dystonia: a case presentation.
Ng A, Galosi S, Salz L, et al.
BMC neurology 2020; (20(1)):246 doi:10.1186/s12883-020-01798-x.
PMID: 32546208 - 15
Dysphagia diagnosis with questionnaire, tongue strength measurement, and FEES in patients with childhood-onset muscular dystrophy.
Printza A, Goutsikas C, Triaridis S, et al.
International journal of pediatric otorhinolaryngology 2019; (117()):198-203 doi:10.1016/j.ijporl.2018.12.005.
PMID: 30579082
This page summarizes symptom-management options for MEPAN syndrome for informational purposes only and does not constitute medical advice. Medication changes, supplements, swallowing evaluations, and DBS decisions should be made with the appropriate healthcare professionals.